Limits...
Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population.

Choi H, Park JY, Shim JS, Kim JH, Bae JH - Int Neurourol J (2013)

Bottom Line: The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV.The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement.Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.

ABSTRACT

Purpose: To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients.

Methods: From January 2010 to March 2013, 165 Korean men with a PSA less than 10 ng/mL who were diagnosed without prostate cancer by prostate biopsy were enrolled. Patients were classified into three age groups: ≤60, 61-70, and >70 years old. The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV.

Results: Enrolled patients had a median age of 63.5 years (44 to 80), a median tPSA of 5.72 ng/mL, a median fPSA of 0.98 ng/mL and a median PV of 53.68 mL, respectively. Among the associations between tPSA, fPSA, age, and PV, the highest correlation was verified between fPSA and PV (r=0.377, P<0.0001); the correlation coefficient between tPSA and PV was much lower (r=0.262, P<0.001). All stratified age cohorts showed the same findings. The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement.

Conclusion: Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.

No MeSH data available.


Related in: MedlinePlus

Receiver operating characteristic (ROC) curves estimating various prostate volumes of total prostate-specific antigen (PSA) and free PSA (fPSA). The areas under the curve of ROC curve for fPSA and PSA as methods used to estimate prostate volume by prostate volume cutoff points (A) <30 mL, (B) 30-40 mL, and (C) >50 mL. AUC, area under the curve.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3713245&req=5

Figure 1: Receiver operating characteristic (ROC) curves estimating various prostate volumes of total prostate-specific antigen (PSA) and free PSA (fPSA). The areas under the curve of ROC curve for fPSA and PSA as methods used to estimate prostate volume by prostate volume cutoff points (A) <30 mL, (B) 30-40 mL, and (C) >50 mL. AUC, area under the curve.

Mentions: The correlation was found in all the cohort group: correlation coefficient 0.198 in less than 61 years old group, 0.403 in 61 to 70 years old group, 0.447 in over than 70 years old group. ROC curves were used to investigate which of fPSA and PSA had a better predictive value for assessing prostate enlargement. Fig. 1 shows ROC curves for prediction of PV (30, 40, and 50 mL) using serum PSA and fPSA.


Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population.

Choi H, Park JY, Shim JS, Kim JH, Bae JH - Int Neurourol J (2013)

Receiver operating characteristic (ROC) curves estimating various prostate volumes of total prostate-specific antigen (PSA) and free PSA (fPSA). The areas under the curve of ROC curve for fPSA and PSA as methods used to estimate prostate volume by prostate volume cutoff points (A) <30 mL, (B) 30-40 mL, and (C) >50 mL. AUC, area under the curve.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3713245&req=5

Figure 1: Receiver operating characteristic (ROC) curves estimating various prostate volumes of total prostate-specific antigen (PSA) and free PSA (fPSA). The areas under the curve of ROC curve for fPSA and PSA as methods used to estimate prostate volume by prostate volume cutoff points (A) <30 mL, (B) 30-40 mL, and (C) >50 mL. AUC, area under the curve.
Mentions: The correlation was found in all the cohort group: correlation coefficient 0.198 in less than 61 years old group, 0.403 in 61 to 70 years old group, 0.447 in over than 70 years old group. ROC curves were used to investigate which of fPSA and PSA had a better predictive value for assessing prostate enlargement. Fig. 1 shows ROC curves for prediction of PV (30, 40, and 50 mL) using serum PSA and fPSA.

Bottom Line: The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV.The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement.Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.

ABSTRACT

Purpose: To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients.

Methods: From January 2010 to March 2013, 165 Korean men with a PSA less than 10 ng/mL who were diagnosed without prostate cancer by prostate biopsy were enrolled. Patients were classified into three age groups: ≤60, 61-70, and >70 years old. The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV.

Results: Enrolled patients had a median age of 63.5 years (44 to 80), a median tPSA of 5.72 ng/mL, a median fPSA of 0.98 ng/mL and a median PV of 53.68 mL, respectively. Among the associations between tPSA, fPSA, age, and PV, the highest correlation was verified between fPSA and PV (r=0.377, P<0.0001); the correlation coefficient between tPSA and PV was much lower (r=0.262, P<0.001). All stratified age cohorts showed the same findings. The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement.

Conclusion: Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.

No MeSH data available.


Related in: MedlinePlus